Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Phase 3CompletedNCT00349180

Sanofi156 enrolled

Overview

This study is performed to confirm the optimal dose for THR (total hip replacement).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

156

Conditions

Arthroplasty, Replacement, Hip

Interventions

Enoxaparin sodiumDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients undergoing elective primary THR (total hip replacement) surgery Exclusion Criteria: * Patient with risk of clinical significant bleeding

Locations (1)

Sanofi-Aventis

Tokyo, Japan

Outcomes

Primary Outcomes

Incidence of VTE

Secondary Outcomes

Incidence of bleeding

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.